# Invivo Capital Partners

> Invivo Capital Partners is a VC fund backing Biotechnology and Pharmaceutical. See 35 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Barcelona, Spain
- Total investments: 35
- Last investment: Jul 2026
- Lead investor: 40%
- Fund size: $44M
- Last fund: Mar 2019
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/invivo-ventures-fcr/
- Website: http://www.invivoventures.es/

Invivo Capital Partners is a VC fund in Barcelona focused on Biotechnology and Pharmaceutical. Invivo Capital is a team of knowledgeable professionals with the scientific, technical, and financial know-how required to analyze and make investments that provide value to the invested company. They also have a network of contacts and key strategic relationships in the health ecosystem.

## Contacts

5 contacts available for Invivo Capital Partners. Shizune tracks 2 team members at Invivo Capital Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/invivo-capital-partners?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $1.6M–$13M |
| Series A | $2.2M–$70M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 8 | 23% |
| Pharmaceutical | 4 | 11% |
| Health Care | 2 | 6% |
| Life Science | 2 | 6% |
| Therapeutics | 2 | 6% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 9 | 26% |
| Funding Round | 5 | 14% |
| Series A | 3 | 9% |
| Series B | 1 | 3% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Spain | 7 | 20% |
| France | 3 | 9% |
| Belgium | 1 | 3% |
| Denmark | 1 | 3% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Albert Ferrer | Founding Partner | 12 | https://shizune.co/investors/profile/albert-ferrer |
| Lluis Pareras | Partner | 14 | https://shizune.co/investors/profile/lluis-pareras |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Telum Therapeutics | Telum Therapeutics is a biotechnology company that develops new treatments for infectious diseases based on the use of lytic enzymes from bacteriophages. | $20.5M | Series A | Jul 01, 2026 |  |
| Telum Therapeutics | Telum Therapeutics is a biotechnology company that develops new treatments for infectious diseases based on the use of lytic enzymes from bacteriophages. | $20.5M | Series A | Jul 01, 2026 |  |
| Telum Therapeutics | Telum Therapeutics is a biotechnology company that develops new treatments for infectious diseases based on the use of lytic enzymes from bacteriophages. | $20.5M | Series A | Jul 01, 2026 |  |
| Signadori Bio | Signadori Bio is the next-generation cellular immunotherapy for cancer cure.This has culminated in the creation of a groundbreaking biotech venture in the cell and gene space that is set to advance innovative approaches in oncology. | $13M | Seed | May 06, 2026 |  |
| ARTHEx Biotech | ARTHEx Biotech S.L. is a spin-off company of the University of Valencia that is developing antisense RNA treatments against genetic diseases. Our team has a strong background on drug discovery and microRNAs involvement in neuromuscular diseases. We are supported by world-renowned scientific and clinical advisors that will facilitate the successfuldevelopment of our products. | $40.6M | Series B | Sep 17, 2025 |  |
| ARTHEx Biotech | ARTHEx Biotech S.L. is a spin-off company of the University of Valencia that is developing antisense RNA treatments against genetic diseases. Our team has a strong background on drug discovery and microRNAs involvement in neuromuscular diseases. We are supported by world-renowned scientific and clinical advisors that will facilitate the successfuldevelopment of our products. | $40.6M | Series B | Sep 17, 2025 |  |
| Integra Therapeutics | Integra Therapeutics is a developer of next generation of gene editing tools to cure diseases. | $12.6M | Seed | Sep 08, 2025 |  |
| Signadori Bio | Signadori Bio is the next-generation cellular immunotherapy for cancer cure.This has culminated in the creation of a groundbreaking biotech venture in the cell and gene space that is set to advance innovative approaches in oncology. |  |  | Mar 18, 2025 |  |
| Signadori Bio | Signadori Bio is the next-generation cellular immunotherapy for cancer cure.This has culminated in the creation of a groundbreaking biotech venture in the cell and gene space that is set to advance innovative approaches in oncology. |  | Seed | Mar 18, 2025 |  |
| Neumirna Therapeutics | Founded in 2020, NEUmiRNA focuses on achieving transformative disease modification for neurological conditions. | $20.6M | Series A | Jan 08, 2025 |  |

10 of 35 investments shown.

## Co-investors
- [AdBio partners](https://shizune.co/investors/profile/advent-france-biotechnology) — VC Fund, 8 deals together
- [CDTI Innovación's INNVIERTE program](https://shizune.co/investors/profile/cdti-innovaci%C3%B3n-s-innvierte-program) — VC Fund, 8 deals together
- [Centre for the Development of Industrial Technology (CDTI)](https://shizune.co/investors/profile/centre-for-the-development-of-industrial-technology-cdti) — VC Fund, 5 deals together
- [Clave Capital](https://shizune.co/investors/profile/clave) — VC Fund, 5 deals together
- [Columbus Venture Partners](https://shizune.co/investors/profile/columbus-venture-partners) — VC Fund, 5 deals together
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund, 4 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [ENISA](https://shizune.co/investors/profile/enisa-2) — VC Fund
- [Inveready](https://shizune.co/investors/profile/inveready-technology-investment-group) — VC Fund
- [Angels Capital](https://shizune.co/investors/profile/angels-capital) — VC Fund

## Featured in investor lists
- [Biotechnology Investors in Spain](https://shizune.co/investors/biotechnology-investors-spain)
- [Biotechnology VC Funds in Spain](https://shizune.co/investors/biotechnology-vc-funds-spain)
- [Biotech Investors in Spain](https://shizune.co/investors/biotech-investors-spain)
- [Biotech VC Funds in Spain](https://shizune.co/investors/biotech-vc-funds-spain)
- [Health Care Investors in Spain](https://shizune.co/investors/health-care-investors-spain)
- [Health Care VC Funds in Spain](https://shizune.co/investors/health-care-vc-funds-spain)

## FAQ

### What does Invivo Capital Partners invest in?

Invivo Capital Partners invests primarily in Biotechnology, Pharmaceutical and Health Care startups, most often at Seed and Funding Round stage. Most of the 35 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Invivo Capital Partners's check size?

Invivo Capital Partners typically joins rounds of $1.6M–$13M at Seed and $2.2M–$70M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Invivo Capital Partners participates in.

### How do I contact Invivo Capital Partners?

Public channels for Invivo Capital Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Invivo Capital Partners?

The team at Invivo Capital Partners includes Albert Ferrer (Founding Partner) and Lluis Pareras (Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co